studies

mRCC - L1 - PDL1 positive, atezolizumab based treatment vs. VEGF(R) inhibitor, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias progression or deaths (PFS)detailed resultsIMmotion-150 (At - PDL1>1%), 2018 1.03 [0.63; 1.68] IMmotion-150 (AtB - PDL1>1%), 2018 0.64 [0.38; 1.08] 0.82[0.51; 1.31]IMmotion-150 (At - PDL1>1%), 2018, IMmotion-150 (AtB - PDL1>1%), 2018241%224moderatenot evaluable objective responses (ORR)detailed resultsIMmotion-150 (At - PDL1>1%), 2018 1.06 [0.46; 2.42] IMmotion-150 (AtB - PDL1>1%), 2018 2.34 [1.05; 5.20] 1.59[0.73; 3.46]IMmotion-150 (At - PDL1>1%), 2018, IMmotion-150 (AtB - PDL1>1%), 2018246%224moderatenot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-09-28 00:44 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 152 - treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons